“7x tested” sounds rigorous. The number tells you almost nothing.

The number is marketing shorthand, not a recognized grade

Official quality frameworks do not rank peptide material by how many times it was “tested.” ICH Q2(R2) organizes analytical work by purpose—identity, assay or potency, purity, impurities, and other quantitative or qualitative measurements—and asks whether each procedure is fit for that purpose.[1] FDA’s synthetic-peptide guidance likewise emphasizes impurity characterization and orthogonal methods, meaning methods that answer the same or adjacent questions through genuinely different analytical principles.[2]

The distinction matters because seven checks are not necessarily seven independent tests. A seller might count purity, identity, content, endotoxin, sterility, metals, and residual solvents. Another may count HPLC results from several vials as several “rounds.” A third may include appearance or document fields. All can arrive at seven; they do not provide the same evidence.

The orthogonality test

Different methods answer different questions

A purity percentage is not a molecular identity result. A correct molecular mass is not a sterility result. A sterility test does not detect endotoxin. The strongest panels are useful because their methods cover different failure modes—not because the total is numerically impressive.

Bachem’s quality-control guide similarly separates the questions “is it the desired product?”, “how pure is it?”, “what by-products are present?”, and “how high is the product content?”[5] FDA’s teriparatide review materials specifically recommend orthogonal chromatographic methods and high-resolution tandem mass spectrometry to characterize and match impurity peaks.[3]

Market snapshot · July 28, 2026

The same multiplier currently describes different programs

We checked public seller pages named in the supplied research brief. This is a purposive snapshot, not a market-wide survey, and seller pages can change. It evaluates what the pages disclose—not whether an undisclosed test occurred.

These differences do not prove dishonesty. They show why the multiplier cannot validate itself. “Conformity,” in particular, is not a single standardized peptide assay: it might mean repeated-vial agreement, appearance, reconstitution behavior, or chromatographic agreement. Ask which.

Cost and time reality

Real testing is plausible—but broad panels leave operational fingerprints

Public laboratory pricing shows that independent multi-method panels are economically possible at batch scale. One peptide-focused lab currently posts $189–$289 for identity, HPLC purity, and net content, with separately priced endotoxin, sterility, heavy-metals, and bioburden work.[8] Those numbers are vendor-posted list prices, not universal market rates or proof of laboratory accreditation.

Eagle Analytical lists 14–18 calendar days for USP <71> sterility and two business days for USP <85> bacterial endotoxin testing.[7] That makes a useful plausibility check: a claim of conventional compendial sterility should leave time for incubation, unless a validated alternative rapid method is clearly identified.

COA checklist

What to request instead of trusting the badge

A COA improves visibility into a sample. It does not transform an RUO product into an approved drug or replace manufacturing controls, stability data, or clinical evidence. FDA continues to treat therapeutic marketing context—not an RUO disclaimer alone—as evidence of intended drug use.[12]